Jingtai Holdings (2228.HK) FY2025 Quick Earnings Review: Revenue +55%, Turns Loss into Profit
📊 Gentron Holdings (2228.HK) FY2025 Earnings Quick Review
Release Date: 2026-03-25
Data Source: HKEX Announcements, Company Financial Reports
🔑 Key Highlights
| Metric | FY2025 | YoY | Interpretation |
|---|---|---|---|
| Revenue | ¥803 million | +55%+ | Rapid growth |
| Net Profit | ¥135 million | Turned to profit | Profit inflection point |
| Net Profit Margin | 16.8% | - | Healthy level |
📈 Business Structure
Dual-engine driven: - Drug Discovery Solutions: ¥538 million (67%) — Cash cow business - AI4S Smart Solutions: ¥265 million (33%) — Growth engine
Strategic Transformation: AI4S business evolved from a single solution → a cross-industry enabling platform (Biopharma + New Materials + Chemical)
🎯 Strategic Highlights
1. Multi-Agent System
- Supports end-to-end R&D workflow
- Reduces manual intervention, improves efficiency
- Enhances competitiveness in the AI for Science field
2. Cross-industry Expansion
- Biopharma: Traditional strength, continuous deepening
- New Materials/Chemical: Large market space, less competition
- Top-tier Endorsement: Successfully deployed a BASF advanced automation workstation in 2025
Data Source: HKEX Announcements, Company Financial Reports
Disclaimer: This analysis is for reference only and does not constitute investment advice.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
